NYSE · Healthcare
BIO-RAD LABORATORIES, INC. (BIO)
As-reported financials and recent SEC filings for BIO-RAD LABORATORIES, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.58B
Net income
$759.9M
Net margin
29.4%
Diluted EPS
$27.85
ROE
10.2%
P/E (TTM)
50.0×
Market cap
$8.05B
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B |
| Operating income | $47.2M | $269.0M | $337.8M | $482.6M | $500.3M |
| Net income | $759.9M | $-1.84B | $-637.3M | $-3.63B | $4.25B |
| Diluted EPS | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-05-28
View on EDGAR →42026-05-13
View on EDGAR →SD2026-05-13
View on EDGAR →1442026-05-11
View on EDGAR →S-82026-04-30
View on EDGAR →10-Q2026-04-30
View on EDGAR →8-K2026-04-30
View on EDGAR →42026-04-28
View on EDGAR →Go deeper on BIO
Search BIO-RAD LABORATORIES, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.